Zofran Dosing for 31-Pound (14 kg) Child
For a 31-pound (14 kg) child, administer ondansetron 4 mg orally three times daily for chemotherapy-induced nausea/vomiting, or a single 4 mg dose for acute gastroenteritis or postoperative nausea/vomiting.
Weight-Based Dosing Framework
The FDA label establishes that pediatric patients 4-11 years old should receive 4 mg three times daily for chemotherapy-induced nausea/vomiting 1. This aligns with weight-based dosing of approximately 0.15 mg/kg, which for a 14 kg child equals approximately 2.1 mg, but the practical dosing uses the 4 mg tablet formulation.
Key Dosing Considerations by Indication:
For Chemotherapy-Induced Nausea/Vomiting:
- 4 mg orally three times daily (first dose 30 minutes before chemotherapy, then every 8 hours)
- Continue for 1-2 days after chemotherapy completion
- This dosing showed 58% complete response rates in pediatric studies 1
For Acute Gastroenteritis (Single Dose):
- Weight-based: 0.15-0.2 mg/kg (approximately 2-3 mg for 14 kg child)
- Practical dose: 2-4 mg as single oral disintegrating tablet
- Research demonstrates no superiority of higher doses (0.13-0.26 mg/kg range showed equivalent efficacy) 2
For Postoperative Nausea/Vomiting:
- Single 4 mg dose administered either before induction or 30 minutes before surgery completion
- Late administration (near end of surgery) shows better efficacy for delayed PONV 3
Critical Age-Related Pharmacokinetic Factors
Important caveat for younger children: If this child is under 6 months old, ondansetron clearance is significantly reduced (31-76% lower depending on age) 4. For infants 1-6 months, reduce dose to 0.1 mg/kg and monitor closely, as standard dosing produces excessive drug exposure.
For children over 6 months (which a 31-pound child almost certainly is), standard pediatric dosing applies without adjustment.
Practical Administration
- Use oral disintegrating tablets (ODT) for ease of administration in children
- No food restrictions, though bioavailability slightly increases with meals 5
- Maximum daily dose: 12 mg (three 4 mg doses) for chemotherapy protocols
- Single doses up to 8 mg are safe but offer no additional benefit over 4 mg in this weight range
Safety Profile
Ondansetron is remarkably well-tolerated in pediatric patients. The most common adverse effects are mild headache and constipation. No dose-limiting toxicity occurs even at doses up to 0.48 mg/kg 6. Importantly, ondansetron does not cause dystonic reactions or akathisia unlike other antiemetics 6.
Avoid ondansetron with immunotherapy: If this child is receiving checkpoint inhibitors (unlikely but possible), use ondansetron cautiously as corticosteroids (often co-administered) may attenuate immunotherapy benefit 7.